Big Screen Entertainment CEO Invited to Judge for Biggest

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jul 20, 2014 at 3:00 AM

Big Screen Entertainment CEO Invited to Judge for Biggest Talent Show in China -- Deadline Extended for Entries

HOLLYWOOD, CA--(Marketwired - Jul 18, 2014) - Big Screen Entertainment Group ( PINKSHEETS : BSEG ) is excited to announce that award-winning producer, BSEG CEO Kimberley Kates, has been selected to be the first American judge on the panel for CCTV's (China Central Television) "Chinese New Year Gala" which airs to over one billion viewers. Ms. Kates will join the judges in the Los Angeles Competition.

This is the first time the show has ever been open to North America. BSEG is acting as an associate producer with American New Era TV.

"I'm honored to be part of this extraordinary opportunity. The beauty of all forms of art and entertainment is an excellent way of building our cultural relations." -- Kimberley Kates

The finale show broadcasts live on the Chinese New Year Eve in Beijing, China. The show airs between 8:00 PM and 12:30 AM and includes 40-50 performances. The CCTV "Chinese New Year Gala" has broadcast live since 1983 and is one of the top viewed shows in the world.

All types of talent may register, from singing, dancing, musical acts, comedy acts, magicians, and any other exceptional, unique talents will be considered.

Registration has been extended to July 25^th , 2014.

"I Want to Be on The Show"

Registration now through July 25^th 1st Round Auditions in six USA locations, July 26-31st 2nd Round: Semi-finals in six USA locations, August 3rd Round: Finals, August 28th, Los Angeles and Las Vegas Final Competition: Finalists showcase on CCTV in Beijing September 16, 2014

Registration website: http://www.neweratvus.com/en/gala/home.html

ABOUT BIG SCREEN ENTERTAINMENT - Big Screen Entertainment ( PINKSHEETS : BSEG ) a publicly traded media company in entertainment and education with a diversified presence in production, television, education and global distribution.

www.bigscreenent.com

Forward-Looking Statements: A number of statements contained in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including timely development, and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions and the ability to secure additional sources of financing. When used in this press release, words such as "could," "plan," "estimate," "expect," "intend," "may," "potential," "should," and similar expressions are forward-looking statements.

Contact: Jensen Zheng Jensen@bigscreenent.com 323.960.3410

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Top 5 Most Recently Viewed Articles

Revolutionizing Knee Treatment with Overture's Latest System

Full Commercial Launch of the OvertureTi Knee Resurfacing System Overture Orthopaedics is making headlines as it proudly announces the full commercial launch of its advanced OvertureTi Knee Resurfacing System. This medical device targets early osteoarthritis and cartilage defects effectively, presenting a breakthrough for patients seeking alternatives to traditional joint...

Elis SA: Key Insights on Recent Share Buyback Activities

Elis SA's Recent Share Buyback Activities Elis SA has made a mark with its recent trading activities associated with its own shares, particularly highlighting a series of transactions carried out during a specified period. Overview of the Buyback Program As part of its strategic financial planning, Elis has engaged in a buyback program that has garnered attention. The...

Kevin O'Leary's Essential Advice for Startups on Content Investment

O'Leary: Tools Are Cheap, But Talent Isn't Entrepreneur and "Shark Tank" star Kevin O'Leary emphasizes a critical insight for startups: while the cost of creating digital content has drastically reduced, the true value comes from the talent that produces it. O'Leary shared his thoughts in a recent video, indicating that although the cost of technology has significantly...

The St. James Reinvents Lacrosse with Spencer Ford at the Helm

The St. James Strengthens Lacrosse Initiatives In an exciting development, The St. James has appointed Spencer Ford as the new Director of Lacrosse, ushering in a transformative approach to lacrosse for both boys and girls. With a vast wealth of experience spanning nearly twenty years, Ford is not only a seasoned professional player but also an accomplished coach and...

Hudbay Minerals Celebrates Permit Approval for Copper World

Hudbay Minerals Receives Final Permit for Copper World Project Hudbay Minerals Inc. (TSX, NYSE: HBM), a prominent player in the mining industry, has taken a significant step forward by securing the final major permit necessary for its Copper World project in Arizona. This milestone not only enhances the company’s operational capacity but also solidifies its commitment...